197 related articles for article (PubMed ID: 34113094)
1. Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials.
Begg M; Hamblin JN; Jarvis E; Bradley G; Mark S; Michalovich D; Lennon M; Wajdner HE; Amour A; Wilson R; Saunders K; Tanaka R; Arai S; Tang T; Van Holsbeke C; De Backer J; Vos W; Titlestad IL; FitzGerald JM; Killian K; Bourbeau J; Poirier C; Maltais F; Cahn A; Hessel EM
Int J Chron Obstruct Pulmon Dis; 2021; 16():1621-1636. PubMed ID: 34113094
[TBL] [Abstract][Full Text] [Related]
2. An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial.
Cahn A; Hamblin JN; Robertson J; Begg M; Jarvis E; Wilson R; Dear G; Leemereise C; Cui Y; Mizuma M; Montembault M; Van Holsbeke C; Vos W; De Backer W; De Backer J; Hessel EM
Int J Chron Obstruct Pulmon Dis; 2021; 16():1607-1619. PubMed ID: 34113093
[TBL] [Abstract][Full Text] [Related]
3. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Fahy WA; Homayoun-Valiani F; Cahn A; Robertson J; Templeton A; Meeraus WH; Wilson R; Lowings M; Marotti M; West SL; Tabberer M; Hessel EM
Int J Chron Obstruct Pulmon Dis; 2021; 16():1637-1646. PubMed ID: 34113095
[TBL] [Abstract][Full Text] [Related]
4. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Khindri S; Cahn A; Begg M; Montembault M; Leemereise C; Cui Y; Hogg A; Wajdner H; Yang S; Robertson J; Hamblin JN; Ludwig-Sengpiel A; Kornmann O; Hessel EM
J Pharmacol Exp Ther; 2018 Dec; 367(3):405-413. PubMed ID: 30217958
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Nemiralisib in Chronic Obstructive Pulmonary Disease: A Systematic Review.
Yang H; He S; Liang L; Pan J
Clin Ther; 2024 Apr; 46(4):360-367. PubMed ID: 38503629
[TBL] [Abstract][Full Text] [Related]
7. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
Begg M; Amour A; Jarvis E; Tang T; Franco SS; Want A; Beerahee M; Fernando D; Karkera Y; Sander C; Southworth T; Singh D; Clark J; Nejentsev S; Okkenhaug K; Condliffe A; Chandra A; Cahn A; Hall EB
Pulm Pharmacol Ther; 2023 Apr; 79():102201. PubMed ID: 36841351
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
10. Sputum Cytokine Profiling in COPD: Comparison Between Stable Disease and Exacerbation.
Barta I; Paska C; Antus B
Int J Chron Obstruct Pulmon Dis; 2022; 17():1897-1908. PubMed ID: 36017119
[TBL] [Abstract][Full Text] [Related]
11. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
[TBL] [Abstract][Full Text] [Related]
12. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.
Gupta V; Khan A; Higham A; Lemon J; Sriskantharajah S; Amour A; Hessel EM; Southworth T; Singh D
Int Immunopharmacol; 2016 Jun; 35():155-162. PubMed ID: 27049289
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
14. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Beeh KM; Beier J; Candler H; Wittig T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
[TBL] [Abstract][Full Text] [Related]
15. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Moretti M; Fagnani S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
[TBL] [Abstract][Full Text] [Related]
16. Reactive oxygen species in peripheral blood and sputum neutrophils during bacterial and nonbacterial acute exacerbation of chronic obstructive pulmonary disease.
Vaitkus M; Lavinskiene S; Barkauskiene D; Bieksiene K; Jeroch J; Sakalauskas R
Inflammation; 2013 Dec; 36(6):1485-93. PubMed ID: 23872721
[TBL] [Abstract][Full Text] [Related]
17. Airway clearance techniques for chronic obstructive pulmonary disease.
Osadnik CR; McDonald CF; Jones AP; Holland AE
Cochrane Database Syst Rev; 2012 Mar; (3):CD008328. PubMed ID: 22419331
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Acute Exacerbation in Subjects with Moderate-to-very Severe COPD by Modulating Lower Respiratory Microbiome: Protocol of a Prospective, Multicenter, Randomized Controlled Trial.
Hua JL; Hu WP; Zuo YH; Zhang J
Int J Chron Obstruct Pulmon Dis; 2020; 15():2985-2990. PubMed ID: 33235447
[TBL] [Abstract][Full Text] [Related]
19. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.
Andreas S; Testa M; Boyer L; Brusselle G; Janssens W; Kerwin E; Papi A; Pek B; Puente-Maestu L; Saralaya D; Watz H; Wilkinson TMA; Casula D; Di Maro G; Lattanzi M; Moraschini L; Schoonbroodt S; Tasciotti A; Arora AK; Maltais F;
Lancet Respir Med; 2022 May; 10(5):435-446. PubMed ID: 35026180
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of the sputum microbiome in COPD exacerbations and correlations between clinical indices.
Su L; Qiao Y; Luo J; Huang R; Li Z; Zhang H; Zhao H; Wang J; Xiao Y
J Transl Med; 2022 Feb; 20(1):76. PubMed ID: 35123490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
